Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -396.09% is 331% below its 5-year average of -91.90%, around the middle of its 5-year range (-917.34%–-24.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.58% below its 12-month average of -389.92%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -396.09%.
RETURN ON EQUITY (ROE)
-396.09%
RETURN ON EQUITY (ROE) AVG TTM
-389.92%
RETURN ON EQUITY (ROE) AVG 3Y
-136.05%
RETURN ON EQUITY (ROE) AVG 5Y
-91.90%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-1.58%
CURRENT VS 3Y AVG
-191.14%
CURRENT VS 5Y AVG
-330.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-842.84%
vs the sector median at left
Kodiak Sciences Inc.
Market Cap
$5.78B
Return on Equity (ROE)
-396.09%
TTM Avg
-389.92%
3Y Avg
-136.05%
5Y Avg
-91.90%
Market Cap
$5.79B
Return on Equity (ROE)
-39.33%
TTM Avg
-54.18%
3Y Avg
-65.89%
5Y Avg
-59.69%
Market Cap
$5.87B
Return on Equity (ROE)
12.33%
TTM Avg
0.28%
3Y Avg
12.51%
5Y Avg
-14.51%
Market Cap
$5.89B
Return on Equity (ROE)
-15.40%
TTM Avg
-48.41%
3Y Avg
-63.30%
5Y Avg
-53.67%
Market Cap
$5.61B
Return on Equity (ROE)
-21.80%
TTM Avg
-16.70%
3Y Avg
-22.00%
5Y Avg
-23.98%
Market Cap
$5.95B
Return on Equity (ROE)
20.38%
TTM Avg
5.87%
3Y Avg
3.40%
5Y Avg
3.36%
Market Cap
$5.53B
Return on Equity (ROE)
-1.93%
TTM Avg
-0.70%
3Y Avg
0.57%
5Y Avg
0.69%
Market Cap
$5.52B
Return on Equity (ROE)
-9.09%
TTM Avg
-8.34%
3Y Avg
-4.98%
5Y Avg
-4.98%
Market Cap
$6.23B
Return on Equity (ROE)
-94.50%
TTM Avg
-115.58%
3Y Avg
-102.12%
5Y Avg
-85.25%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | $5.78B | -396.09% | -389.92% | -136.05% | -91.90% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | -39.33% | -54.18% | -65.89% | -59.69% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 12.33% | 0.28% | 12.51% | -14.51% |
| GRAIL Inc. (GRAL)vs › | $5.89B | -15.40% | -48.41% | -63.30% | -53.67% |
| CG Oncology Inc. (CGON)vs › | $5.61B | -21.80% | -16.70% | -22.00% | -23.98% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 20.38% | 5.87% | 3.40% | 3.36% |
| RadNet, Inc. (RDNT)vs › | $5.53B | -1.93% | -0.70% | 0.57% | 0.69% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | -9.09% | -8.34% | -4.98% | -4.98% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | -94.50% | -115.58% | -102.12% | -85.25% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | N/A | -149.71% | -15.45% | -6097.55% |
ROE
-396.1%
ROA
-94.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -396.09% |
| 2026-03-31 | -205.76% |
| 2025-12-31 | -146.12% |
| 2025-09-30 | -917.34% |
| 2025-06-30 | -284.29% |
| 2025-03-31 | -175.14% |
| 2024-12-31 | -117.25% |
| 2024-09-30 | -103.37% |
| 2024-06-30 | -92.16% |
| 2024-03-31 | -96.50% |
| 2023-12-31 | -98.01% |
| 2023-09-30 | -89.75% |
| 2023-06-30 | -88.18% |
| 2023-03-31 | -78.68% |
| 2022-12-31 | -76.54% |
| 2022-09-30 | -74.35% |
| 2022-06-30 | -65.36% |
| 2022-03-31 | -52.27% |
| 2021-12-31 | -40.25% |
| 2021-09-30 | -30.35% |
| 2021-06-30 | -24.25% |
| 2021-03-31 | -19.37% |
| 2020-12-31 | -15.46% |
| 2020-09-30 | -36.24% |
| 2020-06-30 | -25.35% |
| 2020-03-31 | -19.46% |
| 2019-12-31 | -13.71% |
| 2019-09-30 | -77.75% |
| 2019-06-30 | -63.53% |
| 2019-03-31 | -50.57% |
| 2018-12-31 | -47.73% |
| 2018-06-30 | -195.01% |
